These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 18623218)
41. [Cladribine treatment of repeatedly-relapsed Langerhans cell histiocytosis: a case report and literature review]. Yao X; Ying H; Weihong Z; Qing S; Xintian L Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):296-9. PubMed ID: 26182506 [TBL] [Abstract][Full Text] [Related]
42. Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine. Parker WB; Shaddix SC; Gilbert KS; Shepherd RV; Waud WR Cancer Chemother Pharmacol; 2009 Jul; 64(2):253-61. PubMed ID: 19002461 [TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Nabhan C; Davis N; Bitran JD; Galvez A; Fried W; Tolzien K; Foss S; Dewey WM; Venugopal P Cancer; 2011 Apr; 117(7):1490-7. PubMed ID: 21425150 [TBL] [Abstract][Full Text] [Related]
44. Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience. Barba P; Sampol A; Calbacho M; Gonzalez J; Serrano J; Martínez-Sánchez P; Fernández P; García-Boyero R; Bueno J; Ribera JM Am J Hematol; 2012 Jun; 87(6):631-4. PubMed ID: 22431002 [TBL] [Abstract][Full Text] [Related]
45. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol]. Huang JB; Xue HM; Chen YY; Huang K Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709 [TBL] [Abstract][Full Text] [Related]
46. [Treatment of Langerhans cells histiocytosis by cladribin reached long-term complete remission in 9 out of 10 adult patients]. Adam Z; Szturz P; Duraš J; Pour L; Krejčí M; Rehák Z; Koukalová R; Navrátil M; Hájek R; Král Z; Mayer J Klin Onkol; 2012; 25(4):255-61. PubMed ID: 22920165 [TBL] [Abstract][Full Text] [Related]
47. Clofarabine in relapsed lymphoma: what is the optimal dose? Nabhan C Leuk Lymphoma; 2009 Jul; 50(7):1230-1; author reply 1232-4. PubMed ID: 19557647 [No Abstract] [Full Text] [Related]
48. Isolation and characterization of a murine P388 leukemia line resistant to clofarabine. Waud WR; Gilbert KS; Parker WB; Secrist JA Nucleosides Nucleotides Nucleic Acids; 2011 Nov; 30(11):826-38. PubMed ID: 22060549 [TBL] [Abstract][Full Text] [Related]
49. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside. Apollonsky N; Lipton JM J Pediatr Hematol Oncol; 2009 Jan; 31(1):53-6. PubMed ID: 19125089 [TBL] [Abstract][Full Text] [Related]
51. Clofarabine: emerging role in leukemias. Sampat K; Kantarjian H; Borthakur G Expert Opin Investig Drugs; 2009 Oct; 18(10):1559-64. PubMed ID: 19715446 [TBL] [Abstract][Full Text] [Related]
52. Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia. Baytan B; Ozdemir O; Gunes AM; Dönmez O J Pediatr Hematol Oncol; 2010 Mar; 32(2):144-6. PubMed ID: 20057324 [TBL] [Abstract][Full Text] [Related]
53. Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis. Irie M; Nakano T; Katayama S; Suzuki T; Moriya K; Watanabe Y; Suzuki N; Saitoh-Nanjyo Y; Onuma M; Rikiishi T; Niizuma H; Sasahara Y; Kure S Cancer Rep (Hoboken); 2022 Aug; 5(8):e1579. PubMed ID: 34725963 [TBL] [Abstract][Full Text] [Related]
54. Successful treatment with 2-chlorodeoxyadenosine of refractory pediatric Langerhans cell histiocytosis with initial involvement of the gastrointestinal tract. Mayumi A; Imamura T; Sakamoto K; Ota T; Osone S; Usami I; Hosoi H Int J Hematol; 2019 Dec; 110(6):756-762. PubMed ID: 31350665 [TBL] [Abstract][Full Text] [Related]
55. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Dhall G; Finlay JL; Dunkel IJ; Ettinger LJ; Kellie SJ; Allen JC; Egeler RM; Arceci RJ Pediatr Blood Cancer; 2008 Jan; 50(1):72-9. PubMed ID: 17455311 [TBL] [Abstract][Full Text] [Related]
56. Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children. Uppuluri R; Ramachandrakurup S; Subburaj D; Bakane A; Raj R Pediatr Blood Cancer; 2017 Jan; 64(1):110-112. PubMed ID: 27555565 [TBL] [Abstract][Full Text] [Related]
57. Induction of complete remission using single agent clofarabine in a patient with primary refractory acute myeloblaste leukemia. Douer D; Watkins K; Levine AM; Weiss JM; Marshall LC; Craig AR Leuk Lymphoma; 2003 Dec; 44(12):2135-6. PubMed ID: 14959859 [TBL] [Abstract][Full Text] [Related]
58. 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Pardanani A; Phyliky RL; Li CY; Tefferi A Mayo Clin Proc; 2003 Mar; 78(3):301-6. PubMed ID: 12630583 [TBL] [Abstract][Full Text] [Related]
59. Clofarabine in the treatment of myelodysplastic syndromes. Bryan J; Kantarjian H; Prescott H; Jabbour E Expert Opin Investig Drugs; 2014 Feb; 23(2):255-63. PubMed ID: 24410313 [TBL] [Abstract][Full Text] [Related]
60. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Steinherz PG; Shukla N; Kobos R; Steinherz L Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]